Notice of AGM and Resignation of Director

Source: RNS
RNS Number : 4356O
Iofina PLC
15 May 2024
 

15 May 2024

 

Iofina plc

("Iofina", the "Company" or the "Group")

(AIM: IOF)

 

Notice of AGM, Resignation of Director and Investor Webinar

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today announces that its 2024 Annual General Meeting ('AGM') will take place on 13 June 2024 at 10:00 a.m. at the offices of Canaccord Genuity, 88 Wood Street, London EC2V 7QR.  The Notice of AGM is being posted to shareholders and a copy of the Notice will be made available on the Company's website.

 

Dr. William ("Bill") D. Bellamy, Chair of the Remuneration Committee, will retire as a Director of the Company at the close of the AGM and is therefore not being submitted for re-appointment in the business of the meeting.

 

Commenting on Dr. Bellamy retiring from the Board, Dr. Tom Becker, CEO and President said: "On behalf of everyone, I would like to thank Bill for his services to Iofina over the last ten years. His expertise and practical experience have played an important role in Iofina's evolution in becoming a significantly stronger Company. We wish him well in his future endeavours and travels."

 

Investor Webinar

 

Iofina will hold a live investor session via the Investor Meet Company platform on Wednesday 22 May 2024 at 1:00pm BST. The session will discuss the recent FY23 results along with the Company's forthcoming corporate strategy.

 

The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00 am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet Iofina via: https://www.investormeetcompany.com/iofina-plc/register-investor. Those investors who already follow Iofina on the Investor Meet Company platform will automatically be invited.

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Henry Fitzgerald-O'Connor/Harry Rees

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

 

Media Contact:

Charles Goodwin/Shivantha Thambirajah/Zara McKinlay

Yellow Jersey PR Limited

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

 

LEI: 213800QDMFYVRJYYTQ84

 

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns, and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates six producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine-based products. Iofina Chemical celebrated its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

 

www.iofina.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUSVNRSOUVAAR